Aspect Biosystems adds Dr. Nancy Krieger, Dr. Don Haut, and Dr. Devyn Smith to its Board of Directors

– CANADA, Vancouver – Aspect Biosystems, a biotechnology company pioneering the development of bioprinted tissue therapeutics, today announced the appointments of Dr. Nancy Krieger (MD), Dr. Don Haut (Ph.D.), and Dr. Devyn Smith (Ph.D.) to its Board of Directors.

About Dr. Nancy Krieger

the Dr. Nancy Krieger is CMO of Talaris Therapeutics, a recently public late-clinical stage cell therapy biotech. She has over 18 years of global experience in the biopharmaceutical industry, including leadership positions at Bristol Myers Squibb and Novartis in areas spanning solid organ and stem cell transplantation, immunology, rare disorders, and chronic kidney and liver diseases. Before joining the industry, Dr. Krieger had an active practice in liver transplantation and a basic science laboratory. She completed her transplant fellowship at the University of Wisconsin and general surgical residency at Stanford University, including a postdoctoral fellowship in Stanford’s immunology department.

Dr. Krieger earned her MD at Columbia University College of Physicians and Surgeons.

“I am thrilled to be joining the Board of Aspect Biosystems,” said Dr. Nancy Krieger. “As a transplant surgeon, I am passionate about the tremendous potential of Aspect’s 3D bioprinting technology for regenerative cellular therapies, with the ultimate possibility of replacing organ transplants without the need for life-long immunosuppression.”

About Dr. Don Haut

Dr. Don Haut is currently the CEO of Carmine Therapeutics, a discovery-stage, non-viral gene therapy company with operations in Boston and Singapore. Throughout his career, Dr. Haut has completed transactions exceeding $8 billion. As CBO of AskBio, he led the firm’s business development activities and spearheaded AskBio’s $4 billion acquisition by Bayer AG. Originally trained as a molecular biologist before joining McKinsey, Dr. Haut has since held senior business roles at 3M Company, Smith & Nephew, The Medicines Company, Promedior, Histogenics, Sherlock Bio, and AskBio.

He earned his Ph.D. in Molecular Biology from the Medical School at the University of Missouri-Columbia, and an MBA from Washington University’s Olin School of Business.

“When I first learned about what Aspect Biosystems was doing, my first thought was ‘Wow!’” said Dr. Don Haut. “My second thought was ‘it would be great to work with those folks – they are really onto something.’ So, I am delighted to be joining Aspect – the team, the technology, and the mission are all outstanding.”

About Dr. Devyn Smith

Dr. Devyn Smith joined Arbor Biotechnologies as CEO in 2021 after concluding his role as COO of Sigilon Therapeutics. Before Sigilon, Dr. Smith worked in various roles at Pfizer Inc., including COO of the UK-based Neusentis Unit focused on discovering and developing cell therapies.

He received his Ph.D. in Genetics from Harvard Medical School. He is an inventor on multiple patents and has published in leading scientific journals throughout his career. Dr. Smith is a board member and officer for the Alliance for Regenerative Medicine, the leading international advocacy organization dedicated to realizing the promise of regenerative medicines and advanced therapies.

“I am excited to join the board of Aspect Biosystems,” said Dr. Devyn Smith. “I look forward to partnering with Tamer and the talented team at Aspect to build a successful company that delivers novel cellular therapies to patients with high unmet needs.”

About Aspect Biosystems

Aspect Biosystems is a biotechnology company creating bioprinted tissue therapeutics to transform how we treat disease. Aspect is combining its proprietary bioprinting technology, therapeutic cells, biomaterials, and computational design to create a pipeline of allogeneic tissues that replace or repair damaged organ functions. The company is also partnering with leading researchers and industry innovators worldwide to tackle the biggest challenges in regenerative medicine.

For more information: https://www.aspectbiosystems.com/

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.